Sergio Amaro
A5072926393- Acute Ischemic Stroke Management
- Cerebrovascular and Carotid Artery Diseases
- Traumatic Brain Injury and Neurovascular Disturbances
- Stroke Rehabilitation and Recovery
- Venous Thromboembolism Diagnosis and Management
- Intracranial Aneurysms: Treatment and Complications
- Intracerebral and Subarachnoid Hemorrhage Research
- Gout, Hyperuricemia, Uric Acid
- Vascular Malformations Diagnosis and Treatment
- Cerebrospinal fluid and hydrocephalus
- Neurosurgical Procedures and Complications
- Neuroinflammation and Neurodegeneration Mechanisms
- S100 Proteins and Annexins
- Blood Pressure and Hypertension Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Lipoproteins and Cardiovascular Health
- Advanced MRI Techniques and Applications
- Peripheral Artery Disease Management
- Neurological Disorders and Treatments
- COVID-19 and healthcare impacts
- Inflammasome and immune disorders
- Cardiovascular Health and Disease Prevention
- Advanced X-ray and CT Imaging
- Cardiovascular and exercise physiology
- Advanced Neuroimaging Techniques and Applications
Hospital Clínic de Barcelona
2016-2025
Universitat de Barcelona
2015-2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015-2024
Fundació Clínic per a la Recerca Biomèdica
2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2024
Health and Education Research Management and Epidemiologic Services (United States)
2023
Clinical Trial Investigators
2022
Hospital Universitari de Vic
2020-2021
Biomedical Research Institute
2015-2020
University Hospital and Clinics
2018
Background and Purpose— Mechanical thrombectomy using stent retriever devices have been advocated to increase revascularization in intracranial vessel occlusion. We present the results of a large prospective study on use Solitaire Flow Restoration patients with acute ischemic stroke. Methods— Thrombectomy for Acute Revascularization was an international, multicenter, prospective, single-arm anterior circulation strokes treated within 8 hours symptom onset. Strict criteria site selection were...
The purpose of the study is to analyze how coronavirus disease 2019 (COVID-19) pandemic affected acute stroke care in a Comprehensive Stroke Center.On February 28, 2020, contingency plans were implemented at Hospital Clinic Barcelona contain COVID-19 pandemic. Among them, decision refrain from reallocating Team and Unit patients with COVID-19. From March 1 31, we measured number emergency calls Emergency Medical System Catalonia (7.5 million inhabitants), Codes dispatched Barcelona. We...
<h3>Importance</h3> It is estimated that only 27% of patients with acute ischemic stroke and large vessel occlusion who undergo successful reperfusion after mechanical thrombectomy are disability free at 90 days. An incomplete microcirculatory might contribute to these suboptimal clinical benefits. <h3>Objective</h3> To investigate whether treatment adjunct intra-arterial alteplase improves outcomes following reperfusion. <h3>Design, Setting, Participants</h3> Phase 2b randomized,...
BackgroundEndovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect EVT for medium or distal vessels unclear.MethodsWe randomly assigned participants an isolated (occlusion the nondominant codominant M2 segment middle cerebral artery [MCA]; M3 M4 MCA; A1, A2, A3 anterior artery; P1, P2, P3 posterior artery) receive plus best medical alone within 24 hours after participant was last seen well. primary outcome level disability at 90 days,...
The number of circulating monocytes increases after stroke. In this study, we assessed the time course and phenotype monocyte subsets their relationship with clinical outcome in 46 consecutive stroke patients 13 age-matched controls. proportion most abundant ‘classical’ CD14 high CD16 did not change stroke, whereas that CD16+ increased dim decreased. + had highest expression TLR2, HLA-DR angiogenic marker, Tie-2; costimulatory CD86 adhesion molecule CD49d. Platelet-monocyte interactions were...
Uric acid is a natural antioxidant that protects the brain in model of transient focal ischemia rats. Here we sought to investigate whether uric was protective thromboembolic rats, and global benefit recombinant tissue plasminogen activator (rt-PA) improved by combined treatment. Adult male Sprague-Dawley rats underwent either middle cerebral artery occlusion (MCAO) or sham operation. (16 mg/kg) injected intravenously (i.v.). 20 mins after mCaO, whereas rt-PA (10 administered i.v. at 3 h. A...
Uric acid (UA) is a neuroprotective antioxidant that improves the benefits of alteplase in experimental ischemia. However, it unknown whether endogenous UA also influences response to thrombolysis patients with stroke.A total 317 consecutive treated were included prospective stroke registry. Demographics, laboratory data, neurological course, and infarction volume prospectively collected. Excellent outcome was defined as achieving modified Rankin Scale score <2 at 90 days. Binary ordinal...
Background and Purpose— A progressive decline in the odds of favorable outcome as time to reperfusion increases is well known. However, impact specific workflow intervals not clear. Methods— We studied mechanical thrombectomy group (n=103) prospective, randomized REVASCAT (Randomized Trial Revascularization With Solitaire FR Device Versus Best Medical Therapy Treatment Acute Stroke due Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours Symptom Onset) trial. defined 3...
Background and Purpose— It is unknown whether women men with acute ischemic stroke respond similar to an antioxidant regimen administered in combination thrombolysis. Here, we investigated the independent effect of sex on response uric acid (UA) therapy patients treated alteplase. Methods— In Efficacy Study Combined Treatment With Uric Acid rtPA Acute Ischemic Stroke (URICO-ICTUS) trial, 206 205 were randomized UA 1000 mg or placebo. this reanalysis primary outcome was rate excellent at 90...
Computed tomographic (CT) high attenuation (HA) areas after endovascular therapy for acute ischemic stroke are a common finding indicative of blood-brain barrier disruption. Dual-energy CT allows an accurate differentiation between HA related to contrast staining (CS) or brain hemorrhage (BH). We sought evaluate the prognostic significance presence CS and BH therapy.A prospective cohort 132 patients treated with was analyzed. According dual-energy findings, were classified into 3 groups: no...
A study was undertaken to test in a subgroup reanalysis of the URICO-ICTUS trial whether uric acid is superior placebo improving functional outcome patients with acute stroke and hyperglycemia.Patients were part trial, double-blind that compared administration versus treated alteplase within 4.5 hours onset. The effect therapy on rate excellent at 90 days (modified Rankin Scale ≤ 2) each tertile admission glucose assessed multivariate adjusted models 409 421 randomized who had available...
Whether intravenous thrombolysis adds a further benefit when given before endovascular thrombectomy (EVT) is unknown. Furthermore, delays time to groin puncture, mainly among drip and ship patients.Using region-wide registry data, we selected cases that received direct EVT or combined thrombolysis+EVT for anterior circulation strokes between January 2011 October 2015. Treatment effect was estimated by stratification on propensity score. The average odds ratios the association of treatment...
Stroke is an enormous public health problem with imperative need for more effective therapy. Recombinant tissue plasminogen activator the only licensed drug acute stroke, but its efficacy may be limited by toxicity of compound and reperfusion injury. The coadministration neuroprotective drugs could augment value thrombolytic therapy, evidence in support this approach scarce. use free radical trapping NXY-059, either or without recombinant activator, was not successful Phase III studies....
Identification of neuroprotective therapies in acute ischemic stroke is imperative. We report a predefined analysis the URICO-ICTUS trial (Efficacy Study Combined Treatment With Uric Acid and r-tPA Acute Ischemic Stroke) assessing efficacy uric acid (UA) compared with placebo to prevent early worsening (EIW) relevance collateral circulation.URICO-ICTUS was double-blind, placebo-controlled, phase 2b where total 411 patients treated alteplase within 4.5 hours onset were randomized (1:1)...
Background and Purpose— Less than half of acute ischemic stroke patients treated with mechanical thrombectomy obtain permanent clinical benefits. Consequently, there is an urgent need to identify mechanisms implicated in the limited efficacy early reperfusion. We evaluated predictors prognostic significance vessel wall permeability impairment its association blood–cerebrospinal fluid barrier (BCSFB) disruption after thrombectomy. Methods— A prospective cohort stent retrievers was analyzed....
Background Numerous neuroprotective drugs have failed to show benefit in the treatment of acute ischemic stroke, making search for new treatments imperative. Uric acid is an endogenous antioxidant it a drug candidate improve stroke outcomes. Aim To report effects uric therapy patients receiving intravenous thrombolysis and mechanical thrombectomy. Methods Forty-five with proximal vessel occlusions enrolled URICO-ICTUS trial received recombinant tissue plasminogen activator within 4.5 h after...
We sought to explore the safety and efficacy of new TREVO stent-like retriever in consecutive patients with acute stroke.We conducted a prospective, single-center study 60 (mean age, 71.3 years; male 47%) stroke lasting <8 hours anterior circulation (n=54) or <12 vertebrobasilar (n=6) treated if CT perfusion/CT angiography confirmed large artery occlusion, ruled out malignant profile, showed target mismatch symptoms >4.5 hours. Successful recanalization (Thrombolysis In Cerebral Infarction...
We sought to assess outcomes after endovascular treatment/therapy of acute ischemic stroke, overall and by subgroups, looked for predictors outcome.We used data from a mandatory, population-based registry that includes external monitoring completeness, which assesses reperfusion therapies consecutive patients with stroke since 2011. described subgroups (age ≤ or >80 years; onset-to-groin puncture >6 hours; anterior posterior strokes; previous IV recombinant tissue-type plasminogen activator...